Biotech | December 22, 2021
Piramal Pharma takes a minority stake in Yapan Bio
The investment in Yapan Bio allows Piramal Pharma Solutions to broaden its service offerings in the fast-growing biologics CDMO space
The investment in Yapan Bio allows Piramal Pharma Solutions to broaden its service offerings in the fast-growing biologics CDMO space
It’s the company’s fourth manufacturing site worldwide. Others are located in the US, UK and China
Transformational partnership establishes PCI as a CDMO and broadens capabilities across drug product lifecycle
This new lyophilizer is equipped with systems to best protect high value Active Pharmaceutical Ingredients (APIs) and doubles the lyophilization capacity at the site
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
He will be responsible for the company's overall strategy and provide the necessary direction and dynamic leadership to R&D, manufacturing, business development, and commercial operations
He will be stationed at the company HQ in Bengaluru, India
Proceeds from the IPO will be used for the expansion of the Dehradun facility.
This acquisition marks PPS’ foray into the development and manufacturing of peptide APIs
Subscribe To Our Newsletter & Stay Updated
